关于知识管理中心的概述,用于阐明可使用药物的基因组
Tudor I Oprea1, Cristian Bologa1, Jayme Holmes1
1Translational Informatics Division, Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.
Drug discovery today
|January 13, 2024
概括
知识管理中心 (KMC) 汇总蛋白质数据以确定未经研究的目标. 该资源通过对蛋白质进行分类并提供访问至关重要的信息,有助于药物发现.
科学领域:
- 基因组学就是基因组学.
- 蛋白质组学是指蛋白质组学.
- 生物信息学是一种生物信息学.
背景情况:
- 照亮可药性基因组 (IDG) 项目侧重于研究不足的蛋白质.
- 一个集中的知识库对于理解蛋白质功能和治疗潜力至关重要.
研究的目的:
- 建立知识管理中心 (KMC),以聚合和阐述以蛋白质为中心的数据.
- 开发用于研究研究不足的蛋白质的信息平台和工具.
主要方法:
- 从70多个资源收集和分析数据.
- 编制目标中央资源数据库 (TCRD) 和Pharos平台.
- 根据现有知识将蛋白质分类为目标发育水平 (TDL).
主要成果:
- 创建目标中央资源数据库 (TCRD) 和Pharos网络平台.
- 整合实验,计算和文本挖掘数据的蛋白质结构,化合物相互作用和疾病关联.
- 缺乏研究的蛋白质标的识别和分类.
结论:
- 该KMC有效地汇总和阐述蛋白质知识,支持IDG项目的目标.
- 开发的资源,包括TCRD和Pharos,有助于研究药物发现的研究不足的目标.
- TDL分类有助于优先考虑对具有治疗潜力的蛋白质的研究工作.
相关概念视频
Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


